CHAD65 and CHA2DS2-VASc risk stratification tools for patients with atrial fibrillation a review of clinical effectiveness and guidelines
The purpose of this report is to review the clinical effectiveness of the CHAD65 and CHA2DS2-VASc risk stratification tools compared to each other or to CHADS2 to determine the need for pharmacological treatment in patients with atrial fibrillation (AF). Additionally, this report aims to review evid...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, May, 2017
|
| Series: | CADTH rapid response report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this report is to review the clinical effectiveness of the CHAD65 and CHA2DS2-VASc risk stratification tools compared to each other or to CHADS2 to determine the need for pharmacological treatment in patients with atrial fibrillation (AF). Additionally, this report aims to review evidence-based guidelines regarding the use of the CHAD65 and CHA2DS2-VASc risk stratification tools to determine the need for pharmacological treatment in patients with atrial fibrillation |
|---|---|
| Item Description: | "May 12, 2017." |
| Physical Description: | 1 PDF file (39 pages) illustration |